Gastrointestinal Cancers | Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gastrointestinal Cancers — Part 2 of a Special 3-Part Edition

Featuring an interview with Dr Kanwal Raghav, including the following topics: Activity and tolerability of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing colorectal cancer (CRC) (0:00) Case: A woman in her mid 50s with multiregimen-refractory metastatic CRC receives T-DXd on a clinical trial (11:19) Case: A woman in her early 60s with advanced intrahepatic cholangiocarcinoma receives zanidatamab on a clinical trial (18:11) Molecular pathways and mechanisms of HER2 in cancer; clinical implications and future directions for gastrointestinal cancers (20:33) Evolving paradigm surrounding HER2 and other oncogene-addicted targets (29:32) CME information and select publications